The key to the success of omission of surgery trials is the prediction or the evaluation of residual tumor on imaging. That’s the initial evaluation. And plus the imaging, we will probably need biopsych confirmation, tissue confirmation through vacuum assisted biopsy. We will have to look into the results from the JCOC 1806 trial where a lot of those patients did not even have a biopsey. And a lot the patients that did receive biopisy, they didn’t pre-specify the number of cores, the size of the needle, or anything like that...
The key to the success of omission of surgery trials is the prediction or the evaluation of residual tumor on imaging. That’s the initial evaluation. And plus the imaging, we will probably need biopsych confirmation, tissue confirmation through vacuum assisted biopsy. We will have to look into the results from the JCOC 1806 trial where a lot of those patients did not even have a biopsey. And a lot the patients that did receive biopisy, they didn’t pre-specify the number of cores, the size of the needle, or anything like that. so we will have to see the IMPACT of not specifying the modality of the biopsy and not doing the biopsies at all in those patients, which were pretty early in the stage. But I truly believe that the imaging findings after neurodegenerative therapy may not be enough. We have a lot of studies that show that. So to make it safe, imaging information plus a biopsy of the tumor bed where the tumor used to be before neurodegenerative systemic therapy will add the accuracy about the potential, not potential, about the pathologic CR complete response in the patient and thus provide the evidence for omitting surgery in those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.